ILMN Illumina, Inc.
Health Care · Life Sciences Tools & Services · close $262.54 (2026-10-16) · latest quarter in EDGAR: 2026-06-28
Illumina, Inc. (ILMN) has a ThetaGrade House Rating of 44/100 (grade D), ranking #34 of 150 in Health Care. Its strongest pillars are balance sheet (61) and cash flow (60); its weakest is analyst sentiment (17). TTM revenue growth is 4.9% and operating margin 19.7%.
Data as of .
Analyst sentiment
weight 7.5% · 17| Consensus score (1–5) (3.8%) | derived | 14 |
| 90-day net rating shift (3.8%) | derived | 29 |
Growth
weight 30.83% · 35| Revenue growth YoY (TTM) (12.3%) | 4.9% | 24 |
| EPS growth YoY (TTM) (12.3%) | -32.1% | 23 |
| Revenue acceleration (6.2%) | 4.6% | 81 |
Profitability
weight 18.5% · 54| Operating margin (9.9%) | 19.7% | 68 |
| 4Q gross-margin change (8.6%) | -0.2% | 39 |
Balance sheet
weight 18.5% · 61| Net debt / EBITDA (9.9%) | 0.02× | 70 |
| Current ratio (4.9%) | 1.80 | 37 |
| Interest coverage (3.7%) | 8.74× | 68 |
Cash flow
weight 12.33% · 60| FCF margin (6.2%) | 21.4% | 78 |
| FCF yield (6.2%) | 2.3% | 43 |
Valuation
weight 12.33% · 26| P/E (inverted) (6.2%) | 48.98× | 24 |
| EV/Sales (inverted) (6.2%) | 8.83× | 28 |
Technicals (EOD)
| RSI(14) | 53.1 |
| EMA 9 / 21 | 269.33 / 262.20 |
| 200-day SMA | 169.65 |
| Volume vs 20d avg | 0.57× |
| 20-day return | 7.1% |
Exit-rule monitor
- EXITRating break: House Rating below 60
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: GrossProfit · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like ILMN's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is ILMN's House Rating?
- ILMN scores 44 out of 100 (grade D) as of 2026-10-16, ranking #34 of 150 Health Care stocks we cover.
- What do analysts say about ILMN?
- ThetaGrade's analyst-sentiment pillar for ILMN scores 17/100 against its sector peers, which we read as negative. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
- When does ILMN report earnings next?
- ILMN's next earnings report is estimated for about 2026-10-29 (window 2026-10-22 to 2026-11-05), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is ILMN a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology